Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab and VEGF levels in infants with ROP
NCT03115255Completed
- Sponsor
- Xinhua Hospital
- Start
- May 2017
- Primary completion
- May 2018
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ranibizumab in retinopathy of prematurity (ROP), sponsored by Xinhua Hospital. Primary endpoints: Vascular Endothelial Growth Factor at 1 week and Serum concentration of ranibizumab at 1 week. Started May 2017; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT03115255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03115255.